Skip to content

HUMAW — Hedge Fund Holders & Catalysts | BiotechEdge

BiotechEdgeNew: AI Alerts

Catalysts Convergence Squeeze Signals Cash Runway Insiders Research

Sign In Start 14-Day Free Trial

Home›Companies›Humacyte, Inc. (HUMAW)

Humacyte, Inc.

HUMAW

Held by 1 specialist biotech fund

1 fund opened new positions.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

1.5/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

RA Capital Management

AI Signal

Signal Note: RA Capital Exits Humacyte

RA Capital's exit from HUMAW (bioengineered human acellular vessels for vascular access/grafting) suggests loss of conviction ahead of key clinical milestones or commercial inflection. Humacyte's cash position and path to profitability warrant review—if runway is sub-4Q, the exit may signal dilution concerns that overshadow pipeline upside.

Unlock full AI analysis — 14-day free trial

Position Trend

May 15, 2025

$5.6M

1 fund

Aug 14, 2025

$0

0 funds

Nov 14, 2025

$0

0 funds

Feb 17, 2026

$0

0 funds

-100% total institutional value over 4 quarters

Catalysts

No catalysts tracked.

Position Details

RA Capital ManagementEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

3 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

VOR1 fund BLTE1 fund CAPR1 fund LXEO1 fund MDLN1 fund NAMSW1 fund DSGN1 fund HCAT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: